Simon M. Ametamey,Stefanie Kraemer,Ahmed Haider,Linjing Mu,Bernhard Wuensch
申请号：
US15427952
公开号：
US20170224852A1
申请日:
2017.02.08
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention is directed to benzazepin-1-ol-derived compounds for use in the diagnosis of NMDA receptor-associated diseases or disorders by positron emission tomography (PET). The invention also relates to a method for the diagnosis of NMDA-receptor-associated diseases or disorders by administering to a patient in need of such diagnosis a radioactively labelled compound of the invention in an amount effective for PET imaging of NMDA receptors, recording at least one PET scan, and diagnosing an NMDA-receptor-associated disease or disorder from an abnormal NMDA receptor expression pattern on the PET scan. NMDA-receptor-associated diseases or disorders that can be diagnosed with the radioactively labelled benzazepin-1-ol-derived compounds include but are not limited to neurodegenerative diseases or disorders, Alzheimers disease, depressive disorders, Parkinsons disease, traumatic brain injury, stroke, migraine, alcohol withdrawal and chronic and neuropathic pain.
